CAS 1693731-40-6

CCT251236

CAS : 1693731-40-6

CCT251236

Degré de pureté : ≥98%

Masse moléculaire : 552.62g/mol

Ref: 54-BUP21241

CCT 251236

CAS : 1693731-40-6

CCT 251236 is a small molecule inhibitor of protein synthesis, which belongs to the class of heterobifunctional molecules. It is an orally administered drug with clinical relevance for cancer therapy. CCT 251236 is highly selective for eukaryotic protein synthesis, and has been shown to inhibit the proteasomal activity of the ribosome. This inhibition leads to a decrease in cellular protein content and disrupts protein homeostasis. CCT 251236 has been shown to be effective against primary cells in vitro, as well as in vivo in human clinical studies. CCT 251236 has also been shown to inhibit tumor growth by inducing cell cycle arrest and apoptosis.

Formule : C₃₂H₃₂N₄O₅

Degré de pureté : Min. 95%

Masse moléculaire : 552.62 g/mol

Ref: 3D-BC168608

CCT251236

CAS : 1693731-40-6

CCT251236 is an orally available Pirin ligand obtained from a heat shock transcription factor 1 (hsf1) phenotypic screen.

Formule : C₃₂H₃₂N₄O₅

Degré de pureté : 98.82% - 99.89%

Couleur et forme : Solid

Masse moléculaire : 552.62

Ref: TM-T14905